Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

PMID:
28851100
2.

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J.

Mod Pathol. 2015 Dec;28(12):1528-34. doi: 10.1038/modpathol.2015.112. Epub 2015 Sep 25.

3.

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH.

Pathologe. 2010 May;31(3):208-17. doi: 10.1007/s00292-010-1278-1. German.

PMID:
20443098
4.

Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

Stoss O, Werther M, Zielinski D, Middel P, Jost N, Rüschoff J, Henkel T, Albers P.

Prostate Cancer Prostatic Dis. 2008;11(2):166-72. Epub 2007 Jul 24.

PMID:
17646850

Supplemental Content

Loading ...
Support Center